阿奇霉素序贯治疗小儿支原体肺炎疗效及副作用观察

Effects and safety of Azithromycin sequential therapy in the treatment of mycoplasma pneumonia in children

目的评价阿奇霉素序贯治疗小儿支原体肺炎的疗效及安全性。方法将121例肺炎支原体肺炎的患儿随机分为阿奇霉素序贯组及对照组。阿奇霉素序贯组62例,给予红霉素30mg/(kg.d),分2次静脉滴注,治疗3-5d后予阿奇霉素口服序贯治疗,10mg/(kg.d),每周连服3d停用4d为1疗程,共3疗程;对照组59例,静滴红霉素30mg/(kg.d),分2次静脉滴注,共14d。治疗2周后进行疗效评定及副作用统计。结果阿奇霉素序贯组总有效率90.3%,对照组总有效率71.1%,两者有显著性差异(χ2=10.51,P<0.05);阿奇霉素序贯组总不良反应发生率27.4%,对照组总不良反应发生率67.8%,两者有显著性差异(χ2=13.63,P<0.05)。结论阿奇霉素序贯治疗小儿支原体肺炎有效安全。

Objective To evaluate the effects and safety of Azithromycin sequential therapy in the treatment of mycoplasma pneumonia in children. Methods 121 patients with mycoplasma pneumonia were randomly divided into 2 groups：the Azithromycin sequential group and the control group. （1）The Azithromycin sequential group （62 cases） were given erythromycin 15mg/kg, ivgtt, ql2h for 3-5d at the first stage. At the sequential stage, Azithromycin was administered 10mg/kg, qd, orally from day 1 to day 3 and then stoped for 4 days in a period for 3 periods. （2）The control group （59 cases） were given intravenous erythromycin, 15mg/kg, ivgtt, q12h for 14 days. Clinical response were assessed on day 14. And adverse reactions were counted during the first two weeks. Results Total effective rate was observed in 90.3% and 71.1% of the azithromycin sequential group and control group, respectively. There was significant difference between the two groups （X2=10.51,P〈0.05）. Total adverse reactions rate was observed in 27.4% and 67.8% of the azithromycin sequential group and control group, respectively. There was significant difference between the two groups （x^2=1 3.63, P〈 0.05 ）. Conclusion Azithromycin sequential therapy is safe and effective for the treatment of Mycoplasma pneumonia in children.